• About us
• Contact

Advertisement

Organisation › Details

Point Biopharma Global Inc. (Nasdaq: PNT)

POINT Biopharma Global, Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision oncology by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT's active clinical trials include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-a (FAP-a), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. *

 

	Start	2023-10-03 existent
	Group	Eli Lilly (Group)
	Industry	RADIOPHARMACEUTICAL (RPT)
	Industry 2	oncology
	Person	McCann, Joe (Point Biopharma 202310 CEO)
	Region	Indianapolis, IN
	Country	United States (USA)
	Street	4850 West 78th Street
	City	46268 Indianapolis, IN
	Tel	+1-317-543-9957
		Address record changed: 2023-10-05
Basic data	Employees	n. a.
		* Document for »About Section«: Eli Lilly and Company. (10/3/23). "Press Release: Lilly to Acquire Point Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies". Indianapolis, IN.
		Record changed: 2024-01-20

Advertisement

More documents for Eli Lilly (Group)

• [1] Eli Lilly and Company. (12/27/23). "Press Release: Lilly Completes Acquisition of Point Biopharma". Indianapolis, IN....
• [2] Eli Lilly and Company. (11/17/23). "Press Release: Lilly to Expand Injectable Manufacturing Capacity with Planned $2.5 Billion Site in Germany". Indianapolis, IN....
• [3] Eli Lilly and Company. (11/17/23). "Press Release: Lilly Extends Tender Offer to Acquire Point Biopharma to Dec. 1, 2023". Indianapolis, IN....
• [4] Eli Lilly and Company. (10/3/23). "Press Release: Lilly to Acquire Point Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies". Indianapolis, IN....
• [5] Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin....
• [6] ITM Isotope Technologies Munich SE. (7/31/23). "Press Release: ITM and Point Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177". Garching & Indianapolis, IN....
• [7] Heidelberg Pharma AG. (6/29/23). "Press Release: Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics (ad hoc announcement)". Ladenburg....
• [8] Eckert & Ziegler AG. (4/4/23). "Press Release: Eckert & Ziegler to Supply Point Biopharma with Actinium-225". Berlin & Indianapolis, IN....
• [9] Roche. (3/22/23). "Press Release: Roche Announces Collaboration with Lilly to Enhance Early Diagnosis of Alzheimer's Disease". Basel....
• [10] Boehringer Ingelheim. (1/24/23). "Press Release: US FDA Accepts Supplemental New Drug Application for Jardiance for Adults with Chronic Kidney Disease". Ingelheim & Indianapolis, IN....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.